Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GIM-407 placebo-controlled gluten-challenge study in adults with coeliac disease
ACTRN12626000595314Phase 2Not yet recruiting
- Sponsor
- Georgiamune
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in celiac disease comparing GIM-407 plus gluten challenge with Placebo plus gluten challenge (2 arms). Primary endpoints: Safety and tolerability of GIM-407 and Impact on intestinal villous atrophy. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
GIM-407
03
Conditions
celiac disease
Beyond the preview
Go deeper on ACTRN12626000595314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626000595314.